Bank of Nova Scotia
ACAD icon

Bank of Nova Scotia’s Acadia Pharmaceuticals ACAD Stock Holding History

Bank of Nova Scotia’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-27,436
Closed -$664K – 1155
2022
Q1 		$664K Sell
27,436
-24,827
-48% -$601K ﹤0.01% 1002
2021
Q4 		$1.22M Buy
52,263
+23,537
+82% +$473K ﹤0.01% 954
2021
Q3 		$477K Buy
28,726
+6,286
+28% +$121K ﹤0.01% 1020
2021
Q2 		$547K Buy
+22,440
New +$507K ﹤0.01% 953

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of Nova Scotia's ACAD Position: Q2 2022 in Review

Bank of Nova Scotia sold out of Acadia Pharmaceuticals (ACAD) in Q2 2022, closing a stake of 27,436 shares — an estimated $664K sold.

Bank of Nova Scotia first reported a position in ACAD in Q2 2021 and held it in 4 quarters. The position peaked at $1.22M in Q4 2021. 246 funds tracked by Wall St. Rank hold ACAD as of Q2 2022.

  • Bank of Nova Scotia reported no remaining Acadia Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Bank of Nova Scotia sold 27,436 Acadia Pharmaceuticals shares in Q2 2022, an estimated $664K.
  • Bank of Nova Scotia first reported a position in Acadia Pharmaceuticals in Q2 2021 and held it in 4 quarters.
  • Bank of Nova Scotia's Acadia Pharmaceuticals position peaked at $1.22M in Q4 2021.
  • 246 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2022.

Based on Bank of Nova Scotia's 13F filing for Q2 2022, filed 5 Aug 2022.